Form 4: Day One Biopharmaceuticals COO Charles N. York II Reports Stock Transactions

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reported the acquisition and disposal of common stock and Restricted Stock Units (RSUs) on May 15 and 16, 2024.

Summary

• Charles N. York II, the COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc. (DAWN), filed a Form 4 detailing changes in beneficial ownership.
• On May 15, 2024, York acquired 1,375, 2,250, and 6,625 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• On May 16, 2024, York disposed of 2,675 shares of common stock at a price of $16.0787 per share.
• Following these transactions, York directly owns 224,868 shares of Day One Biopharmaceuticals, Inc.
• The sale of shares was solely to cover the reporting person's tax liability with respect to the settlement of RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and explained, but any insider selling can create slight uncertainty.

Positives

• The vesting of RSUs indicates a continued alignment of the executive's interests with the company's performance.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although the explanation mitigates this concern.

Risks

• While the sale is attributed to tax obligations, consistent selling activity by insiders could create negative market sentiment.

Future Outlook

The RSUs will continue to vest in quarterly installments on February 15, May 15, August 15, and November 15, subject to continued service.

Industry Context

Insider transactions are common in publicly traded companies, and this filing provides transparency into the holdings and transactions of a key executive at Day One Biopharmaceuticals.

Comparison to Industry Standards

• Form 4 filings are a standard requirement for corporate insiders in the US, ensuring transparency in their trading activities.
• The reported transactions are typical for executives receiving stock-based compensation, such as RSUs, and selling shares to cover tax obligations.
• Similar filings can be observed for executives at comparable biopharmaceutical companies like BioMarin, Vertex, and Amgen.

Stakeholder Impact

• Shareholders may monitor insider transactions for insights into management's perspective on the company's value.
• Employees holding company stock or options may be interested in the trading activity of executives.

Key Dates